The made by Moderna (Spikevax®) and Pfizer/BioNTech (Comirnaty®) have both been approved for use in Switzerland. They are comparable in terms of their safety and efficacy. Both offer an efficacy rate of more than 90 percent, and both are associated with similar side effects.
Neither vaccine contains adjuvants, i.e. substances such as aluminium that are added to enhance the immune response. Indeed, the immune response elicited by mRNA vaccines is sufficiently strong.
The two vaccines differ in terms of their . In particular, the lipid nanoparticles used to encapsulate the mRNA are different. The lipid nanoparticle used for the Moderna vaccine allows distributors to store the vaccine longer and at higher temperatures